Suppr超能文献

一种用于癌症治疗药物新组合的I期试验的分层贝叶斯设计。

A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.

作者信息

Braun Thomas M, Wang Shufang

机构信息

Department of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109, USA.

出版信息

Biometrics. 2010 Sep;66(3):805-12. doi: 10.1111/j.1541-0420.2009.01363.x.

Abstract

We propose a hierarchical model for the probability of dose-limiting toxicity (DLT) for combinations of doses of two therapeutic agents. We apply this model to an adaptive Bayesian trial algorithm whose goal is to identify combinations with DLT rates close to a prespecified target rate. We describe methods for generating prior distributions for the parameters in our model from a basic set of information elicited from clinical investigators. We survey the performance of our algorithm in a series of simulations of a hypothetical trial that examines combinations of four doses of two agents. We also compare the performance of our approach to two existing methods and assess the sensitivity of our approach to the chosen prior distribution.

摘要

我们针对两种治疗药物不同剂量组合的剂量限制毒性(DLT)概率提出了一种分层模型。我们将此模型应用于一种自适应贝叶斯试验算法,其目标是识别DLT发生率接近预先指定目标率的组合。我们描述了根据从临床研究人员那里获取的一组基本信息为模型中的参数生成先验分布的方法。我们在一项假设试验的一系列模拟中考察了该算法的性能,该假设试验研究了两种药物四种剂量的组合。我们还将我们方法的性能与两种现有方法进行了比较,并评估了我们的方法对所选先验分布的敏感性。

相似文献

1
A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.
Biometrics. 2010 Sep;66(3):805-12. doi: 10.1111/j.1541-0420.2009.01363.x.
3
A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
Stat Med. 2022 Mar 15;41(6):1059-1080. doi: 10.1002/sim.9316. Epub 2022 Jan 25.
4
Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Stat Med. 2015 Feb 28;34(5):859-75. doi: 10.1002/sim.6376. Epub 2014 Nov 21.
5
Phase I trial design for drug combinations with Bayesian model averaging.
Pharm Stat. 2015 Mar-Apr;14(2):108-19. doi: 10.1002/pst.1668. Epub 2015 Jan 13.
6
Dose-finding design for multi-drug combinations.
Clin Trials. 2011 Aug;8(4):380-9. doi: 10.1177/1740774511408748. Epub 2011 Jun 7.
7
A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
J Biopharm Stat. 2018;28(3):562-574. doi: 10.1080/10543406.2017.1372774. Epub 2017 Oct 6.
9
Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Pharm Stat. 2017 Mar;16(2):114-121. doi: 10.1002/pst.1793. Epub 2016 Nov 28.
10
A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.
Pharm Stat. 2014 May-Jun;13(3):196-207. doi: 10.1002/pst.1618. Epub 2014 Apr 9.

引用本文的文献

1
Seamless monotherapy-combination phase I dose-escalation model-based design.
Clin Trials. 2025 Aug;22(4):430-441. doi: 10.1177/17407745251350604. Epub 2025 Jul 12.
2
Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials.
Stat Biopharm Res. 2025;17(2):266-276. doi: 10.1080/19466315.2024.2370403. Epub 2024 Aug 28.
3
Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology.
JCO Precis Oncol. 2024 Oct;8:e2400275. doi: 10.1200/PO.24.00275. Epub 2024 Oct 21.
4
Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Clin Trials. 2024 Jun;21(3):331-339. doi: 10.1177/17407745241234634. Epub 2024 Mar 30.
5
A NOVEL FRAMEWORK TO ESTIMATE MULTIDIMENSIONAL MINIMUM EFFECTIVE DOSES USING ASYMMETRIC POSTERIOR GAIN AND -TAPERING.
Ann Appl Stat. 2022 Sep;16(3):1445-1458. doi: 10.1214/21-aoas1549. Epub 2022 Jul 19.
6
Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
Braz J Biom. 2022 Dec;40(4):453-468. doi: 10.28951/bjb.v40i4.627. Epub 2022 Dec 30.
7
Local continual reassessment methods for dose finding and optimization in drug-combination trials.
Stat Methods Med Res. 2023 Oct;32(10):2049-2063. doi: 10.1177/09622802231192955. Epub 2023 Aug 18.
8
Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.
J Appl Stat. 2022 Aug 3;50(9):2055-2078. doi: 10.1080/02664763.2022.2105827. eCollection 2023.
9
Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.
Stat Biopharm Res. 2022;14(3):270-282. doi: 10.1080/19466315.2022.2081602. Epub 2022 Aug 2.
10
A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials.
BMC Med Res Methodol. 2023 Mar 2;23(1):57. doi: 10.1186/s12874-023-01867-y.

本文引用的文献

1
Sequential continual reassessment method for two-dimensional dose finding.
Stat Med. 2008 Nov 29;27(27):5664-78. doi: 10.1002/sim.3372.
2
Simultaneously optimizing dose and schedule of a new cytotoxic agent.
Clin Trials. 2007;4(2):113-24. doi: 10.1177/1740774507076934.
3
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Br J Cancer. 2006 Apr 24;94(8):1130-5. doi: 10.1038/sj.bjc.6603072.
7
Two-dimensional dose finding in discrete dose space.
Biometrics. 2005 Mar;61(1):217-22. doi: 10.1111/j.0006-341X.2005.030540.x.
8
Designs for single- or multiple-agent phase I trials.
Biometrics. 2004 Sep;60(3):661-9. doi: 10.1111/j.0006-341X.2004.00215.x.
10
Dose-finding with two agents in Phase I oncology trials.
Biometrics. 2003 Sep;59(3):487-96. doi: 10.1111/1541-0420.00058.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验